ArticlebioRxiv : the preprint server for biology2026
Pan-Cancer Genomic Scars of Alternative End Joining and Single-Strand Annealing.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
DNA double-strand breaks (DSBs) are among the most cytotoxic lesions encountered by cells and represent a major source of genome instability in cancer. The preferred pathway to repair resected DSBs is high-fidelity homologous recombination (HR), but error-prone annealing-dependent pathways such as single-strand annealing (SSA) and alternative end joining (Alt-EJ) generally act as backup repair mechanisms in HR-deficient contexts. However, the extent to which these pathways are engaged across tumor types and how their activity is coupled with HR deficiency remains unclear. In this work, we systematically characterize scars from SSA and Alt-EJ across 2,157 whole-genome-sequenced tumors spanning 17 cancer types, identifying 832 SSA-like and 37,359 Alt-EJ-like deletions in total. We find that Alt-EJ is the predominant backup repair pathway in HR-deficient tumors compared with SSA; however, prostate adenocarcinoma and hepatocellular carcinoma exhibit elevated SSA-like deletion burdens despite low HR-deficiency scores. Moreover, our genome-wide analysis reveals that SSA-like deletions preferentially occur in SINE-rich regions and exhibit pronounced enrichment near transcription start sites in HR-proficient lymphoid lineage tumors. Our results show that SSA- and Alt-EJ-associated genomic scars are not confined to HR-deficient tumors, but are shaped by local genomic and transcriptional context, capturing distinct dimensions of DSB repair activity beyond HR deficiency alone.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.